Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-5-13
pubmed:abstractText
Oxyntomodulin (OXM) is a circulating gut hormone released post prandially from cells of the gastrointestinal mucosa. Given intracerebroventricularly to rats, it inhibits food intake and promotes weight loss. Here we report that peripheral (ip) administration of OXM dose-dependently inhibited both fast-induced and dark-phase food intake without delaying gastric emptying. Peripheral OXM administration also inhibited fasting plasma ghrelin. In addition, there was a significant increase in c-fos immunoreactivity, a marker of neuronal activation, in the arcuate nucleus (ARC). OXM injected directly into the ARC caused a potent and sustained reduction in refeeding after a fast. The anorectic actions of ip OXM were blocked by prior intra-ARC administration of the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin(9-39), suggesting that the ARC, lacking a complete blood-brain barrier, could be a potential site of action for circulating OXM. The actions of ip GLP-1, however, were not blocked by prior intra-ARC administration of exendin(9-39), indicating the potential existence of different OXM and GLP-1 pathways. Seven-day ip administration of OXM caused a reduction in the rate of body weight gain and adiposity. Circulating OXM may have a role in the regulation of food intake and body weight.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0013-7227
pubmed:author
pubmed:issnType
Print
pubmed:volume
145
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2687-95
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:15001546-Animals, pubmed-meshheading:15001546-Appetite Depressants, pubmed-meshheading:15001546-Arcuate Nucleus, pubmed-meshheading:15001546-Darkness, pubmed-meshheading:15001546-Dose-Response Relationship, Drug, pubmed-meshheading:15001546-Drug Administration Schedule, pubmed-meshheading:15001546-Eating, pubmed-meshheading:15001546-Fasting, pubmed-meshheading:15001546-Gastric Emptying, pubmed-meshheading:15001546-Ghrelin, pubmed-meshheading:15001546-Glucagon, pubmed-meshheading:15001546-Glucagon-Like Peptide 1, pubmed-meshheading:15001546-Glucagon-Like Peptides, pubmed-meshheading:15001546-Humans, pubmed-meshheading:15001546-Immunohistochemistry, pubmed-meshheading:15001546-Injections, pubmed-meshheading:15001546-Injections, Intraperitoneal, pubmed-meshheading:15001546-Male, pubmed-meshheading:15001546-Oxyntomodulin, pubmed-meshheading:15001546-Peptide Fragments, pubmed-meshheading:15001546-Peptide Hormones, pubmed-meshheading:15001546-Photoperiod, pubmed-meshheading:15001546-Protein Precursors, pubmed-meshheading:15001546-Rats, pubmed-meshheading:15001546-Rats, Wistar, pubmed-meshheading:15001546-Receptors, Glucagon, pubmed-meshheading:15001546-Weight Gain
pubmed:year
2004
pubmed:articleTitle
Peripheral oxyntomodulin reduces food intake and body weight gain in rats.
pubmed:affiliation
Endocrine Unit, Department of Metabolic Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't